Clinical Trial Update: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of C-CAR039 (Prizloncabtagene Autoleucel) for relapsed/refractory large B-cell lymphoma. The study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• C-CAR039

Snippet

Sponsor: Shanghai AbelZeta Ltd. | Conditions: Relapsed/Refractory Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING